ArticleBMC infectious diseases2025
Higher prevalence of pulmonary tuberculosis revealed by Xpert MTB/RIF ultra among drug users in Kinshasa, Democratic Republic of Congo.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pediatric Tuberculosis in North Kivu: The Urgency of a Targeted Response to a Forgotten Childhood Disease.Public health challenges · 2026Review
- Cox Proportional Hazards Model Analysis of Survival Among Tuberculosis Patients Under Treatment in Mbuji-Mayi, Democratic Republic of the Congo.Journal of multidisciplinary healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Democratic Republic of Congo (DRC) is one of the eight countries with the highest burden of tuberculosis (TB) in the world. The public health system is inadequate and the screening for TB in the key and vulnerable population (KVP), including drug users (DU) is not currently done. The present study aimed to determine the prevalence of pulmonary TB among DU in Kinshasa by comparing molecular tests with microscopic techniques.
methodsA cross-sectional study covering 22 townships (out of 24) of Kinshasa was conducted from October to December 2023. Sputum samples were collected from DUs aged ≥ 18 years, clinically suspected of TB, and attending drug consumption sites. The samples were analyzed by both the Acid-fast bacilli (AFB)-Nelseen hot staining and Xpert MTB/RIF Ultra for TB and rifampin-resistance diagnosis.
resultsFor 399 DUs included in the study, the age range was from 18 to 77 years old, with a median of 31 (IQR: 25-39). Among these DUs, 359 (89%; 95% CI: 86.64- 92.55%) were male. TB prevalence was 3.5% (95% CI: 1.9-5.8%) when the AFB-Nelseen hot staining was used for diagnosis. However, the prevalence was significantly higher at 13.8% (95% CI: 10.6-17.6%) with the Xpert MTB/RIF test (p = 0.000). Xpert MTB-RIF Ultra contributed with an added value of 82% (95% IC: 79.25- 86.47%) to the diagnosis of TB in DUs. The KAPPA test showed a low concordance at 25%. Alcohol, diazepam and tobacco consumption have been identified as practical risks associated with the onset of pulmonary TB (p < 0.05).
conclusionDUs are a population at risk of TB that should not be neglected among all KVPs in Kinshasa. In this specific population, the determination of TB prevalence was significantly improved with the use of Xpert MTB/RIF Ultra compared to hot AFB-Neelsen staining. Among the DU included in the present study, those who habitually consumed alcohol in its different forms, diazepam for non-medical purposes, and tobacco, were significantly more infected than the others. DUs should be considered for systemic screening for pulmonary TB alongside other key populations such as people living with HIV and Xpert should be maintained as a first-line test instead of microscopy. Further studies also including asymptomatic participants are needed to assess the burden due to pulmonary TB in DUs as well as in their living environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.